Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2009-02-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2008.12.085PMID 19138846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.

  2009cited by this paper
• Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

  2009cited by this paper
• Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.

  2008cited by this paper
• Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.

  2008cited by this paper
• Type 2 Diabetes in Children and Adolescents in a 2-Year Follow-Up: Insufficient Adherence to Diabetes Centers

  2007cited by this paper
• Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.

  2007cited by this paper
• Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors.

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Glycogen phosphorylase inhibitors.

  2006cited by this paper
• Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.

  2006cited by this paper
• Development of type 2 diabetes in children and adolescents.

  2006cited by this paper
• Synthesis and structure-activity relationships of 3-phenyl-2-propenamides as inhibitors of glycogen phosphorylase a.

  2006cited by this paper
• Type 2 diabetes in children. An emerging clinical problem

  2006cited by this paper
• Development of type 2 diabetes in children and adolescents

  2006cited by this paper
• Childhood Obesity and Type 2 Diabetes Mellitus

  2005cited by this paper
• Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.

  2005cited by this paper
• A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition.

  2005cited by this paper
• Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.

  2004cited by this paper
• Synthesis of (S)-α-Cyclopropyl-4- phosphonophenylglycine

  2001cited by this paper
• Synthesis of (S)-alpha-cyclopropyl-4-phosphonophenylglycine.

  2001cited by this paper
• Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core.

  2000cited by this paper
• Role of murine cytochrome P-450 2F2 in metabolic activation of naphthalene and metabolism of other xenobiotics.

  1999cited by this paper
• Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study.

  1992cited by this paper
• Evidence for hepatic formation, export and covalent binding of reactive naphthalene metabolites in extrahepatic tissues in vivo.

  1983cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. International Epidemic of Childhood Obesity Childhood Obesity: Public-health Crisis, Common Sense Cure

  year unknowncited by this paper

• Integrative GWAS and RNA-Seq analysis for target identification and virtual drug screening in colorectal cancer

  2025cites this paper
• Current therapeutic targets and multifaceted physiological impacts of caffeine

  2023cites this paper
• Senna petersiana (Bolle) leaf extract modulates glycemic homeostasis and improves dysregulated enzyme activities in fructose-fed streptozotocin-induced diabetic rats.

  2022cites this paper
• Discovery and Biotechnological Exploitation of Glycoside-Phosphorylases

  2022cites this paper
• The Medicinal Chemistry of Caffeine.

  2021cites this paper
• Vanillin Exerts Therapeutic Effects against Hyperglycemia-Altered Glucose Metabolism and Purinergic Activities in Testicular Tissues of Diabetic Rats.

  2021cites this paper
• Crystal structures of eukaryote glycosyltransferases reveal biologically relevant enzyme homooligomers

  2018cites this paper
• The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization

  2018cites this paper
• Exploring the Dual Inhibitory Activity of Novel Anthranilic Acid Derivatives towards α-Glucosidase and Glycogen Phosphorylase Antidiabetic Targets: Design, In Vitro Enzyme Assay, and Docking Studies

  2018cites this paper
• An Improved Comparative Docking Approach for Developing Specific Glycogen Phosphorylase Inhibitors Using Pentacyclic Triterpenes.

  2017cites this paper
• Discovery of new nanomolar inhibitors of GPa: Extension of 2-oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors.

  2017cites this paper
• Computer-Aided Discovery of Glycogen Phosphorylase Inhibitors Exploiting Natural Products

  2017cites this paper
• One-Step Synthesis of Dicarboxamides through Pd-Catalysed Aminocarbonylation with Diamines as N-Nucleophiles

  2015cites this paper
• Predicting Cross-Reactivity from Computational Studies for Pre-evaluation of Specific Hepatic Glycogen Phosphorylase Inhibitors - -insilico Screening of Drugs for Evaluating Specificity

  2015cites this paper
• Synthesis, screening and docking of small heterocycles as glycogen phosphorylase inhibitors.

  2014cites this paper
• Glycogen phosphorylase inhibitors: a patent review (2008 – 2012)

  2013cites this paper
• Anthranilic acid-based diamides derivatives incorporating aryl-isoxazoline pharmacophore as potential anticancer agents: design, synthesis and biological evaluation.

  2012cites this paper
• Structural investigations of anthranilimide derivatives by CoMFA and CoMSIA 3D-QSAR studies reveal novel insight into their structures toward glycogen phosphorylase inhibition

  2011cites this paper
• Docking-Based Comparative Intermolecular Contacts Analysis as New 3-D QSAR Concept for Validating Docking Studies and in Silico Screening: NMT and GP Inhibitors as Case Studies

  2011cites this paper
• Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.

  2010cites this paper
• Recent advances in the allosteric inhibition of glycogen phosphorylase.

  2010cites this paper
• Computation as a tool for glycogen phosphorylase inhibitor design.

  2010cites this paper
• Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

  2009cites this paper